# Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure

> **NCT02263326** · PHASE3 · COMPLETED · sponsor: **Babafemi Taiwo** · enrollment: 89 (actual)

## Conditions studied

- HIV Infection

## Interventions

- **DRUG:** dolutegravir
- **DRUG:** lamivudine
- **DRUG:** Continue current antiretroviral regimen

## Key facts

- **NCT ID:** NCT02263326
- **Lead sponsor:** Babafemi Taiwo
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2017-07
- **Final completion:** 2017-09
- **Target enrollment:** 89 (ACTUAL)
- **Last updated:** 2019-10-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02263326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02263326, "Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02263326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*